Factor VIII Inhibitor Bypassing Activity (FEIBA)

Registered South African indications:

• Treatment and prophylaxis of haemophilia A patients with FVIII inhibitor
• Treatment and prophylaxis of haemophilia B patients with FIX inhibitor

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Disseminated intravascular coagulation
• Acute thrombosis or embolism (including myocardial infarction)

Cautions

• Transmission of  infectious agents 
• Increased erythropoiesis
• Immunodeficiency 
• Pregnancy
• Children below 6 years of age
• Breastfeeding
• Elderly
• Patients on a low sodium diet

Forms avail. in SA and covered in this monograph: inj

Haemophilia A patients with FVIII inhibitor
Haemophilia B patients with FIX inhibitor with:

• Joint, muscle and soft tissue haemorrhage - minor to major bleeding
• Mucous membrane bleeding
• Other severe haemorrhage e.g. central nervous system bleed
• Patients undergoing surgery
• Prophylaxis of bleeding

Treatment should be advised by a Comprehensive Haemophilia Treatment Centre found across South Africa. See Care Coord section for contact numbers.

The dosage and duration of the therapy is dependent upon the severity of the disorder, the location and extent of the bleeding and the patient's clinical condition.

Paed. forms avail. in SA and covered in this monograph: inj

Bleeding prophylaxis

Younger than 6 years

• Not established for use

Older than 6 years

• See adult dosage

Pregnancy

• FDA Pregnancy Category C

Breastfeeding

• Caution, no information available 

Renal Impairment

• No dose adjustment recommended

Hepatic Impairment

• No dose adjustment recommended

Elderly

• Caution; no dose adjustment recommended

Central Nervous System Disorders

• Somnolence
• Dizziness
• Dysgeusia
• Headache

Cardiovascular Disorders

• Hypotension
• Chest pain
• Chest discomfort

Respiratory Disorders

• Dyspnea

Gastrointestinal Disorders

• Nausea

Skin and Subcutaneous Tissue Disorders

• Rash

Immune, Blood and Lymphatic System Disorders

•  Increase in inhibitor titer
•  Hypersensitivity

Others

• Chills
• Pyrexia

• Antifibrinolytics
• Recombinant factor VIIa 

• Coagulation analysis

Factor VIII Inhibitor bypassing activity (FEIBA) is a plasma-derived concentrate containing activated clotting factors.Multiple interactions of the components in FEIBA restore the impaired thrombin generation of hemophilia patients with inhibitors. FEIBA shortens the activated partial thromboplastin time (aPTT) of plasma containing factor VIII inhibitor.

Injection (per ml) 500iu

• FEIBA (Adcock) originator

Injection (per ml) 1000iu

• FEIBA (Adcock) originator